Lingxia Xin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lingxia Xin has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Xiaorong Hou
Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
2 shared publications - Fuquan Zhang
Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
1 shared publication - Fuquan Zhang
Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
1 shared publication - Huanwen Wu
Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
1 shared publication - Jiabin Ma
Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
1 shared publication Kang Ren
Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 25 June 2026
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 18
Exploring the molecular classification-based personalized treatment decision-making in FIGO stage I–III endometrial carcinoma after surgery: a population-based real-world study
Background: Robust real-world evidence supporting the clinical utility of molecular classification in endometrial carcinoma (EC) remains limited. Objectives: To investigate the molecular classification-based personalized treatment decision-making for EC by presenting real-world data, including survival outcomes and failure patterns. Methods: This retrospective cohort study included patients with International Federation of Gynecology and Obstetrics (FIGO) stage I–III EC who underwent initial surgery and had available molecular classification at Peking Union Medical College Hospital, between December 2017 and April 2025. The primary endpoint was disease-free survival (DFS). We evaluated survival outcomes, visualized dynamic annual hazard rates (AHRs), and compared failure patterns across subgroups. Independent prognostic factors were identified using Cox regression analyses. Results: Between December 2017 and April 2025, 267 eligible patients were evaluated. The median age was 55 years, and the median follow-up was 31.10 months. NSMP was the most common molecular subtype (46.8%), followed by MMRd (27.7%), POLEmut (13.1%), and p53abn (12.4%). Endometrioid carcinoma G1-2 was the predominant histological type overall (74.5%). According to FIGO, the 2009 criteria, the stage distribution was as follows: IA (66.7%), IB (20.6%), II (4.5%), and III (12.2%). Restaging under the FIGO 2023 system resulted in upstaging in 20.2% and downstaging in 2.6% of patients. Most patients (56.6%) were classified as low-risk per the ESGO–ESTRO–ESP 2025 risk classification. Although observation alone was used in 45.7% of the entire cohort, intensified treatment was administered to 33.3% of the p53abn subgroup. Excellent 3-year overall survival (OS, 99.2%) and (DFS, 88.4%) were observed in the entire cohort. The p53abn group exhibited the highest recurrence rate (30.3%), frequently presenting as simultaneous multi-site recurrences. No recurrences were observed in the POLEmut group. The p53abn group exhibited the highest recurrence hazard rate (peak: 2.2% at 16.8 months), followed by the MMRd group (peak: 0.8% at 14.0 months) and the NSMP group (peak: 0.3% at 21.0 months). Both the ESGO–ESTRO–ESP 2025 risk classification and FIGO 2023 staging were independent prognostic factors for recurrence. Conclusion: This study provides evidence that molecular classification-based personalized treatment decision-making is feasible and can yield excellent survival outcomes in patients with stage I–III EC.
- 25 June 2026
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 18
Open AccessExploring the molecular classification-based personalized treatment decision-making in FIGO stage I–III endometrial carcinoma after surgery: a population-based real-world study
Background: Robust real-world evidence supporting the clinical utility of molecular classification in endometrial carcinoma (EC) remains limited. Objectives: To investigate the molecular classification-based personalized treatment decision-making for EC by presenting real-world data, including survival outcomes and failure patterns. Methods: This retrospective cohort study included patients with International Federation of Gynecology and Obstetrics (FIGO) stage I–III EC who underwent initial surgery and had available molecular classification at Peking Union Medical College Hospital, between December 2017 and April 2025. The primary endpoint was disease-free survival (DFS). We evaluated survival outcomes, visualized dynamic annual hazard rates (AHRs), and compared failure patterns across subgroups. Independent prognostic factors were identified using Cox regression analyses. Results: Between December 2017 and April 2025, 267 eligible patients were evaluated. The median age was 55 years, and the median follow-up was 31.10 months. NSMP was the most common molecular subtype (46.8%), followed by MMRd (27.7%), POLEmut (13.1%), and p53abn (12.4%). Endometrioid carcinoma G1-2 was the predominant histological type overall (74.5%). According to FIGO, the 2009 criteria, the stage distribution was as follows: IA (66.7%), IB (20.6%), II (4.5%), and III (12.2%). Restaging under the FIGO 2023 system resulted in upstaging in 20.2% and downstaging in 2.6% of patients. Most patients (56.6%) were classified as low-risk per the ESGO–ESTRO–ESP 2025 risk classification. Although observation alone was used in 45.7% of the entire cohort, intensified treatment was administered to 33.3% of the p53abn subgroup. Excellent 3-year overall survival (OS, 99.2%) and (DFS, 88.4%) were observed in the entire cohort. The p53abn group exhibited the highest recurrence rate (30.3%), frequently presenting as simultaneous multi-site recurrences. No recurrences were observed in the POLEmut group. The p53abn group exhibited the highest recurrence hazard rate (peak: 2.2% at 16.8 months), followed by the MMRd group (peak: 0.8% at 14.0 months) and the NSMP group (peak: 0.3% at 21.0 months). Both the ESGO–ESTRO–ESP 2025 risk classification and FIGO 2023 staging were independent prognostic factors for recurrence. Conclusion: This study provides evidence that molecular classification-based personalized treatment decision-making is feasible and can yield excellent survival outcomes in patients with stage I–III EC.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (5)
Annual hazard rates for early-stage endometrial carcinoma after postoperative radiotherapy under FIGO 2023 staging system: results from a population-based single-center cohort study
Xin L, et al. J Gynecol Oncol. 2026 ;37:e107. https://doi.org/10.3802/jgo.2026.37.e107
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (5)
Open AccessAnnual hazard rates for early-stage endometrial carcinoma after postoperative radiotherapy under FIGO 2023 staging system: results from a population-based single-center cohort study
Xin L, et al. J Gynecol Oncol. 2026 ;37:e107. https://doi.org/10.3802/jgo.2026.37.e107